7910 Woodmont Avenue,Suite 1210
Bethesda, Maryland 20814, U.S.A. 
info@mlsvfund.com |   +1 301 298 5455

© 2018  by MASA Life Science Ventures, LP

NEWS

November 21, 2019

Clinical and commercial agreement using MaxCyte’s recently launched ExPERT™ platform enables up to five of Vor’s engineered cell therapies and includes development and approval milestones and sales-based payments 

Takes MaxCyte’s total number of partn...

October 25, 2019

MCY-M11 is being evaluated in relapsed/refractory ovarian cancer and peritoneal mesothelioma

CARMA platform offers faster manufacturing speeds, broader therapeutic applications, combination opportunities and repeat dosing potential

Gaithersburg, Maryla...

October 8, 2019

Gaithersburg, Maryland – October 7, 2019: Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, and MaxCyte, Inc., the global cell-based therapies and life sciences company, today announced a new clinical and commercial license agre...

May 9, 2019

No dose-limiting toxicities or safety concerns observed in first cohort of treated patients. Feasibility of streamlined, faster CAR therapy manufacturing process confirmed. Dosing initiated in second cohort of patients.

Gaithersburg, Maryland – M...

March 1, 2019

Gaithersburg, Maryland – March 1, 2019: MaxCyte, the global cell-based medicines and life sciences company, announced today that it has expanded its relationship with Kite, a Gilead Company, by entering into a multi-drug clinical and commercial agree...

February 6, 2019

London - MaxCyte Inc on Tuesday said it has raised GBP10.0 million from a placing of 5.9 million shares at 170 pence each.

The life sciences company placed 5.9 million shares, representing just over 11% of its issued share capital, at 170 pence each....

January 23, 2019

As published in WuXi AppTec's Innovation That Matters 

Cell therapy offers a treasure chest of new medicines, but there is still much to learn about cell activities and how to deliver these potential benefits before science and the industry can fully...

November 15, 2018

Precision BioSciences gains rights to MaxCyte’s cell engineering technology to develop next-generation, oncology-focused, cell therapies with Precision’s ARCUS® genome-editing technology

DURHAM, NC, and GAITHERSBURG, MD, November 14, 2018 – Precision...

November 10, 2018

CRISPR Therapeutics Gains Additional Rights to MaxCyte’s Cell Engineering Technology to Develop CRISPR/Cas9-Based Cell Therapies in Immuno-Oncology

ZUG, SWITZERLAND, CAMBRIDGE, MASS. and GAITHERSBURG, MD, November 9, 2018 – CRISPR Therapeutics (NASDAQ...

October 10, 2018

First patient dosed in Phase I clinical study to evaluate MaxCyte’s lead CAR therapeutic in ovarian cancer and peritoneal mesothelioma​

Gaithersburg, Maryland –  MaxCyte, the global cell-based medicines and life sciences company, announced today that...

Please reload

Featured Posts
Please reload

See News By Company
See News By Month
Please reload